Sign In
Buy NBIX
$175.77
+1.62 (+0.93%)
At Close: Jul 24, 2026
Neurocrine Biosciences' Crenessity Approval Sets Stage For Diversified Revenue And Growth
10:11am, Wednesday, 18'th Dec 2024
Neurocrine's Ingrezza is forecasted to generate $2.3 billion in revenue in 2024, cementing its role as the company's primary revenue driver. Crenessity's approval for CAH treatment represents a transf
Neurocrine Wins FDA Approval For Genetic Disorder Drug
07:00pm, Friday, 13'th Dec 2024
Neurocrine Biosciences won Food and Drug Administration approval late Friday for the first new treatment for an adrenal disease in decades. The post Neurocrine Wins FDA Approval For Genetic Disorder D
CRENESSITY, the first new treatment available in 70 years to the classic congenital adrenal hyperplasia (CAH) community, offers a paradigm-shifting treatment approach FDA approval supported by data fr
US FDA approves Neurocrine Biosciences' genetic disorder drug
05:50pm, Friday, 13'th Dec 2024
The U.S. Food and Drug Administration has approved Neurocrine Biosciences' drug to treat a type of genetic disorder, the health regulator's website showed on Friday.
Neurocrine Biosciences to Participate at Investor Conferences in December
04:01pm, Tuesday, 26'th Nov 2024
The 7th Annual Evercore HealthCONx Conference on December 3 Citi's 2024 Global Healthcare Conference on December 4 SAN DIEGO , Nov. 26, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX)
Why Neurocrine Biosciences Stock Is Very Attractive At Current Levels
11:02am, Friday, 08'th Nov 2024
Neurocrine Biosciences, Inc.'s August share price decline after the messy phase 2 results of NBI-568 in schizophrenia patients is understandable, but the magnitude is not. Neurocrine is trading at slo
Data Support Positive Impact of INGREZZA in People With Huntington's Disease Chorea Findings Presented at the 2024 Annual Meeting of the Huntington Study Group SAN DIEGO , Nov. 7, 2024 /PRNewswire/ -
Neurocrine Biosciences to Participate at Investor Conferences in November
04:01pm, Tuesday, 05'th Nov 2024
2024 UBS Global Healthcare Conference on November 12 Stifel 2024 Healthcare Conference on November 18 Jefferies London Healthcare Conference on November 19 SAN DIEGO , Nov. 5, 2024 /PRNewswire/ -- Neu
Findings Presented at the 2024 Psych Congress Include Data From More Than 300 Patients SAN DIEGO , Nov. 4, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) presented data from more
SAN DIEGO , Nov. 4, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) presented data from the long-term KINECT®-4 study demonstrating tardive dyskinesia remission in nearly 60% of par
Neurocrine Biosciences, Inc. (NBIX) Q3 2024 Earnings Call Transcript
03:11pm, Wednesday, 30'th Oct 2024
Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Q3 2024 Earnings Conference Call August 30, 2024 8:00 AM ET Company Participants Kyle Gano - Chief Executive Officer Matt Abernethy - Chief Financial Office
Neurocrine (NBIX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
10:35am, Wednesday, 30'th Oct 2024
Although the revenue and EPS for Neurocrine (NBIX) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall
Neurocrine Biosciences (NBIX) Q3 Earnings Miss Estimates
09:16am, Wednesday, 30'th Oct 2024
Neurocrine Biosciences (NBIX) came out with quarterly earnings of $1.24 per share, missing the Zacks Consensus Estimate of $1.47 per share. This compares to earnings of $0.82 per share a year ago.
Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance
07:00am, Wednesday, 30'th Oct 2024
INGREZZA® (valbenazine) Third Quarter Net Product Sales of $613 Million Representing 26% Year-Over-Year Growth INGREZZA ® (valbenazine) 2024 Net Product Sales Guidance Raised to $2.30 - $2.32 Billio
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?
11:07am, Wednesday, 23'rd Oct 2024
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
